FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

E Polationship of Poporting Porcon(s) to Issuer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Chacko Jacob (Last) (First) (Middle) C/O ORIC PHARMACEUTICALS, INC. 240 E. GRAND AVE., 2ND FLOOR (Street) SOUTH SAN FRANCISCO Quantification of Reporting Person (Middle) (Middle) C/O ORIC PHARMACEUTICALS, INC.				Oric Pharmaceuticals, Inc. [ORIC] 3. Date of Earliest Transaction (Month/Day/Year) 09/10/2021 4. If Amendment, Date of Original Filed (Month/Day/Year)						r) ((Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) President and CEO 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(City) (Sta	ate) (Z	Zip)									Person						
	Table	I - Non-Deriv	ative	Secu	rities	s Ac	quir	ed, D	isposed o	f, or	Benefic	cially	Own	ed			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/		2A. Deemed Execution Date, if any (Month/Day/Year)		•, 1	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			nd 5) Secu Bene Own		icially d Following	Forn (D) c Indir	n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership
						ſ	Code	v	Amount	(A) or (D)	Price		Transa	Reported Transaction(s) (Instr. 3 and 4)		tr. 4)	(Instr. 4)
Common Stock 09/10/202		21				S ⁽¹⁾		2,942	D	\$25.07	793(2)	1	13,609		D		
Common Stock 09/13/2		09/13/20	21	L			S ⁽¹⁾		2,801	D	\$25.02	\$25.0228 ⁽³⁾		10,808		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Cod	nsaction le (Instr.	Str. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Expiration Date (Month/Day/Year)		Amo Secu Unde Deriv Secu 3 and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- 2. Represents the weighted average share price of an aggregate total of 2,942 shares sold in the price range of \$25.00 to \$25.28 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. Represents the weighted average share price of an aggregate total of 2,801 shares sold in the price range of \$25.00 to \$25.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

/s/ Christian Kuhlen, attorneyin-fact

** Signature of Reporting Person

09/14/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.